Age gender	Symptome	Primary site	Classification		Primary treatment	Adjuvant treatment	Lymph node	Evolution
Age gender	Symptome	Primary site	Ballantyne	TNM	Primary treatment	Adjuvant treatment	Lymph node	Evolution
61 female	Epistaxis nasalobstruction	Maxillary sinus	I	T3	Surgery (paralateronasal)	Immunochemotherapy radiation		Alive at 11 months
65 female	Epistaxis facial pressure	Maxillary sinus	II	T4	Surgery (paralateronasal)	Immunochemotherapy radiation	N+	Death at 10 months
67 female	nasalobstruction	Nasal cavity	I	T1	Surgery endonasal	Immunochemotherapy radiation		Alive at 61 months
W < 68 female	Epistaxis nasalobstruction	Septum	I	T1	Surgery (paralateronasal)	Immunochemotherapy radiation		Alive at 42 months
68 female	epistaxis	Nasal cacity (cornet inf)	I	T1	Surgery endonasal	Immunochemotherapy radiation		Alive at 18 months
72 female	epistaxis facial pressure	Maxillary sinus	III	T4	Surgery (paralateronasal)	Immunochemotherapy radiation	M+	Death at 07 months
75 female	Epistaxis nasalobstruction	Nasoethmoidal	I	T3	Surgery (paralateronasal)	Immunochemotherapy radiation		Alive at 16 months
61 male	epistaxis facial pressure	Maxillary sinus	II	T4	Surgery (paralateronasal)	Immunochemotherapy radiation	N+	Death at 6 months
67 male	facial pressure	Maxillary sinus	I	T3	Surgery (paralateronasal)	Immunochemotherapy radiation		Death at 9 months
68 male	epistaxis facial pressure	Maxillary sinus	I	T1	Surgery (paralateronasal)	Immunochemotherapy radiation		Alive at 51 months
71 male	Epistaxis nasalobstruction	Nasal cavity	I	T1	Surgery endonasal	Immunochemotherapy radiation		Alive at 31 months
73 male	Epistaxis nasalobstruction	Nasal septum	I	T1	Surgery (paralateronasal)	Immunochemotherapy radiation		Alive at 30 months